Christian Kanstrup
Chief Executive Officer bei EVAXION BIOTECH A/S
Vermögen: 47 090 $ am 31.03.2024
Profil
Christian Kanstrup is currently the Chief Executive Officer at Evaxion Biotech A, Director at NNIT A, and Chairman at Mediq Holding Danmark ApS.
He is also a Director at Novo Nordisk Haemophilia Foundation.
In the past, he worked as a Director at FastPassCorp A, Director at Glycom A, and SVP-Strategy, Access & Marketing at Novo Nordisk A.
He has a graduate degree from the University of Copenhagen and a graduate degree from the International Institute for Management Development.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NNIT A/S
0,01% | 31.12.2023 | 3 000 ( 0,01% ) | 47 090 $ | 31.03.2024 |
Aktive Positionen von Christian Kanstrup
| Unternehmen | Position | Beginn |
|---|---|---|
| NNIT A/S | Director/Board Member | 08.03.2018 |
| EVAXION BIOTECH A/S | Chief Executive Officer | 29.08.2023 |
| Novo Nordisk Haemophilia Foundation | Director/Board Member | - |
Mediq Holding Danmark ApS
 Mediq Holding Danmark ApS Financial ConglomeratesFinance Part of Mediq BV, Mediq Holding Danmark ApS is a Danish company that functions as an investment holding company. The private company is based in Brøndby, Denmark. The company was founded in 2010 by Jesper Schultz Larsen. The CEO is Katrine Bjarkov Benthien. | Chairman | - |
Ehemalige bekannte Positionen von Christian Kanstrup
| Unternehmen | Position | Ende |
|---|---|---|
| FASTPASSCORP A/S | Director/Board Member | 02.03.2019 |
Glycom A/S
 Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Director/Board Member | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Ausbildung von Christian Kanstrup
| University of Copenhagen | Graduate Degree |
| International Institute for Management Development | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| FASTPASSCORP A/S | Technology Services |
| NNIT A/S | Technology Services |
| EVAXION BIOTECH A/S | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Health Technology |
| Novo Nordisk Haemophilia Foundation | |
Mediq Holding Danmark ApS
Mediq Holding Danmark ApS Financial ConglomeratesFinance Part of Mediq BV, Mediq Holding Danmark ApS is a Danish company that functions as an investment holding company. The private company is based in Brøndby, Denmark. The company was founded in 2010 by Jesper Schultz Larsen. The CEO is Katrine Bjarkov Benthien. | Finance |
